The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor

Naruyuki Kobayashi, Shinichi Toyooka, Junichi Sou, Hiromasa Yamamoto, Hideaki Dote, Kensuke Kawasaki, Hiroki Otani, Takafumi Kubo, Masaru Jida, Tsuyoshi Ueno, Midori Ando, Atsuko Ogino, Katsuyuki Kiura, Shinichiro Miyoshi

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), gefitinib and erlotinib, is frequently observed after initiation of TKIs therapy. Non-small-cell lung cancers (NSCLC) with activating EGFR mutations were reported to be sensitive to heat shock protein 90 (Hsp90) inhibitors regardless of the secondary TKI-resistant T790M mutation. We established EGFR-TKI resistant clones for PC-9 cell lines, harboring EGFR exon 19 deletions, with or without the secondary T790M mutation. We examined the anti-proliferative effect of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), an orally active Hsp90 inhibitor, on the growth of NSCLC cell lines in vitro and in vivo. In MTS assay, the IC 50 values of 17-DMAG for 13 EGFR-mutant cell lines including eight EGFR-TKI resistant cell lines ranged from 0.04 to 0.16μM while those for seven EGFR-wild type cell lines ranged from 1.6 to 27.4μM. Western blot analysis revealed that phospho-EGFR, phospho-Akt, phospho-MAPK, cdk4, and cyclin D1 were more readily depleted by 17-DMAG treatment in EGFR-mutant cell lines than in EGFR-wild type cell lines. Cleaved PARP expression confirmed apoptosis in response to 17-DMAG treatment in EGFR-mutant cell lines but not in EGFR-wild type cell lines. In mice xenograft models, 17-DMAG significantly reduced the growth of EGFR-mutant lines irrespective of T790M mutation. These results suggested that 17-DMAG is a potential novel therapeutic agent for NSCLC patients with EGFR mutations with or without EGFR-TKI resistance.

Original languageEnglish
Pages (from-to)161-166
Number of pages6
JournalLung Cancer
Volume75
Issue number2
DOIs
Publication statusPublished - Feb 2012

Fingerprint

17-(dimethylaminoethylamino)-17-demethoxygeldanamycin
HSP90 Heat-Shock Proteins
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Cell Line
Epidermal Growth Factor Receptor
Mutation
Growth Inhibitors
Cyclin D1
Therapeutics

Keywords

  • 17-DMAG
  • Acquired resistance
  • EGFR mutation
  • EGFR-TKI
  • Gefitinib
  • Hsp90
  • Hsp90 inhibitor

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor. / Kobayashi, Naruyuki; Toyooka, Shinichi; Sou, Junichi; Yamamoto, Hiromasa; Dote, Hideaki; Kawasaki, Kensuke; Otani, Hiroki; Kubo, Takafumi; Jida, Masaru; Ueno, Tsuyoshi; Ando, Midori; Ogino, Atsuko; Kiura, Katsuyuki; Miyoshi, Shinichiro.

In: Lung Cancer, Vol. 75, No. 2, 02.2012, p. 161-166.

Research output: Contribution to journalArticle

Kobayashi, Naruyuki ; Toyooka, Shinichi ; Sou, Junichi ; Yamamoto, Hiromasa ; Dote, Hideaki ; Kawasaki, Kensuke ; Otani, Hiroki ; Kubo, Takafumi ; Jida, Masaru ; Ueno, Tsuyoshi ; Ando, Midori ; Ogino, Atsuko ; Kiura, Katsuyuki ; Miyoshi, Shinichiro. / The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor. In: Lung Cancer. 2012 ; Vol. 75, No. 2. pp. 161-166.
@article{9240d26c6eca48dfa0f3362dd83a9435,
title = "The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor",
abstract = "Acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), gefitinib and erlotinib, is frequently observed after initiation of TKIs therapy. Non-small-cell lung cancers (NSCLC) with activating EGFR mutations were reported to be sensitive to heat shock protein 90 (Hsp90) inhibitors regardless of the secondary TKI-resistant T790M mutation. We established EGFR-TKI resistant clones for PC-9 cell lines, harboring EGFR exon 19 deletions, with or without the secondary T790M mutation. We examined the anti-proliferative effect of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), an orally active Hsp90 inhibitor, on the growth of NSCLC cell lines in vitro and in vivo. In MTS assay, the IC 50 values of 17-DMAG for 13 EGFR-mutant cell lines including eight EGFR-TKI resistant cell lines ranged from 0.04 to 0.16μM while those for seven EGFR-wild type cell lines ranged from 1.6 to 27.4μM. Western blot analysis revealed that phospho-EGFR, phospho-Akt, phospho-MAPK, cdk4, and cyclin D1 were more readily depleted by 17-DMAG treatment in EGFR-mutant cell lines than in EGFR-wild type cell lines. Cleaved PARP expression confirmed apoptosis in response to 17-DMAG treatment in EGFR-mutant cell lines but not in EGFR-wild type cell lines. In mice xenograft models, 17-DMAG significantly reduced the growth of EGFR-mutant lines irrespective of T790M mutation. These results suggested that 17-DMAG is a potential novel therapeutic agent for NSCLC patients with EGFR mutations with or without EGFR-TKI resistance.",
keywords = "17-DMAG, Acquired resistance, EGFR mutation, EGFR-TKI, Gefitinib, Hsp90, Hsp90 inhibitor",
author = "Naruyuki Kobayashi and Shinichi Toyooka and Junichi Sou and Hiromasa Yamamoto and Hideaki Dote and Kensuke Kawasaki and Hiroki Otani and Takafumi Kubo and Masaru Jida and Tsuyoshi Ueno and Midori Ando and Atsuko Ogino and Katsuyuki Kiura and Shinichiro Miyoshi",
year = "2012",
month = "2",
doi = "10.1016/j.lungcan.2011.04.022",
language = "English",
volume = "75",
pages = "161--166",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor

AU - Kobayashi, Naruyuki

AU - Toyooka, Shinichi

AU - Sou, Junichi

AU - Yamamoto, Hiromasa

AU - Dote, Hideaki

AU - Kawasaki, Kensuke

AU - Otani, Hiroki

AU - Kubo, Takafumi

AU - Jida, Masaru

AU - Ueno, Tsuyoshi

AU - Ando, Midori

AU - Ogino, Atsuko

AU - Kiura, Katsuyuki

AU - Miyoshi, Shinichiro

PY - 2012/2

Y1 - 2012/2

N2 - Acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), gefitinib and erlotinib, is frequently observed after initiation of TKIs therapy. Non-small-cell lung cancers (NSCLC) with activating EGFR mutations were reported to be sensitive to heat shock protein 90 (Hsp90) inhibitors regardless of the secondary TKI-resistant T790M mutation. We established EGFR-TKI resistant clones for PC-9 cell lines, harboring EGFR exon 19 deletions, with or without the secondary T790M mutation. We examined the anti-proliferative effect of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), an orally active Hsp90 inhibitor, on the growth of NSCLC cell lines in vitro and in vivo. In MTS assay, the IC 50 values of 17-DMAG for 13 EGFR-mutant cell lines including eight EGFR-TKI resistant cell lines ranged from 0.04 to 0.16μM while those for seven EGFR-wild type cell lines ranged from 1.6 to 27.4μM. Western blot analysis revealed that phospho-EGFR, phospho-Akt, phospho-MAPK, cdk4, and cyclin D1 were more readily depleted by 17-DMAG treatment in EGFR-mutant cell lines than in EGFR-wild type cell lines. Cleaved PARP expression confirmed apoptosis in response to 17-DMAG treatment in EGFR-mutant cell lines but not in EGFR-wild type cell lines. In mice xenograft models, 17-DMAG significantly reduced the growth of EGFR-mutant lines irrespective of T790M mutation. These results suggested that 17-DMAG is a potential novel therapeutic agent for NSCLC patients with EGFR mutations with or without EGFR-TKI resistance.

AB - Acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), gefitinib and erlotinib, is frequently observed after initiation of TKIs therapy. Non-small-cell lung cancers (NSCLC) with activating EGFR mutations were reported to be sensitive to heat shock protein 90 (Hsp90) inhibitors regardless of the secondary TKI-resistant T790M mutation. We established EGFR-TKI resistant clones for PC-9 cell lines, harboring EGFR exon 19 deletions, with or without the secondary T790M mutation. We examined the anti-proliferative effect of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), an orally active Hsp90 inhibitor, on the growth of NSCLC cell lines in vitro and in vivo. In MTS assay, the IC 50 values of 17-DMAG for 13 EGFR-mutant cell lines including eight EGFR-TKI resistant cell lines ranged from 0.04 to 0.16μM while those for seven EGFR-wild type cell lines ranged from 1.6 to 27.4μM. Western blot analysis revealed that phospho-EGFR, phospho-Akt, phospho-MAPK, cdk4, and cyclin D1 were more readily depleted by 17-DMAG treatment in EGFR-mutant cell lines than in EGFR-wild type cell lines. Cleaved PARP expression confirmed apoptosis in response to 17-DMAG treatment in EGFR-mutant cell lines but not in EGFR-wild type cell lines. In mice xenograft models, 17-DMAG significantly reduced the growth of EGFR-mutant lines irrespective of T790M mutation. These results suggested that 17-DMAG is a potential novel therapeutic agent for NSCLC patients with EGFR mutations with or without EGFR-TKI resistance.

KW - 17-DMAG

KW - Acquired resistance

KW - EGFR mutation

KW - EGFR-TKI

KW - Gefitinib

KW - Hsp90

KW - Hsp90 inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84855459627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855459627&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2011.04.022

DO - 10.1016/j.lungcan.2011.04.022

M3 - Article

C2 - 21767894

AN - SCOPUS:84855459627

VL - 75

SP - 161

EP - 166

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -